FDA Allows Resumption Of BioNTech/MediLink Therapeutics Partnered Phase 1 Study For Cancer Drug With Lower Dose – BioNTech (NASDAQ:BNTX)
The FDA has lifted the partial medical maintain on MediLink Therapeutics’ Section 1 trial for BNT326/YL202, a HER3-targeting antibody-drug conjugate ...
